A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects

The objective of the study is to evaluate if FS Grifols is non-inferior to EVICEL® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment application (TStart) with no occurrence of rebleeding until the completion of the surgical closure by layers of the exposed surgical field containing the TBS (TClosure).

开始日期2019-01-18

申办/合作机构

Instituto Grifols SA

NCT01754480

/ Completed临床3期

A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgeries

This study is designed to assess the safety and efficacy of Fibrin Sealant Grifols in patients undergoing open surgical procedures where bleeding may be present on parenchymous tissue (e.g., solid abdominal organs such as the liver). The purpose of this study is to demonstrate that Fibrin Sealant Grifols is not inferior to commercially-available oxidized cellulose pads (Surgicel®) in providing benefit in the time to hemostasis (i.e, the stoppage of bleeding). This study has a Preliminary Part (I) for study teams to become familiar with the application of Fibrin Sealant Grifols and to assess safety and a Primary Part (II) to assess the safety and efficacy of Fibrin Sealant Grifols. In both parts of the study, patients will be randomized in a 1:1 ratio to either Fibrin Sealant Grifols or Surgicel.

开始日期2013-03-01

申办/合作机构

Instituto Grifols SA

NCT01731938

/ Completed临床3期

A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries

This study is designed to assess the safety and efficacy of fibrin sealant (FS) Grifols in patients undergoing elective (non-emergency) soft tissue open surgery where bleeding may be present. The purpose of this study is to demonstrate that FS Grifols is not inferior to commercially-available oxidized cellulose pads (Surgicel®) in providing benefit in the time to hemostasis (i.e, the stoppage of bleeding). This study has a Preliminary Part (I) for study teams to become familiar with the application of FS Grifols and a Primary Part (II) to assess the safety and efficacy of FS Grifols. In both parts of the study, patients will be randomized in a 1:1 ratio to either FS Grifols or Surgicel.

开始日期2012-11-01

申办/合作机构

Grifols Biologicals, Inc.

[+1]

100 项与纤维蛋白粘合剂（Grifols）相关的临床结果

登录后查看更多信息

100 项与纤维蛋白粘合剂（Grifols）相关的转化医学

登录后查看更多信息

100 项与纤维蛋白粘合剂（Grifols）相关的专利（医药）

登录后查看更多信息

项与纤维蛋白粘合剂（Grifols）相关的文献（医药）

2024-11-01·JOURNAL OF PEDIATRIC SURGERY

A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery

Article

作者: Balanescu, Laura ; Slavkovic, Andjelka ; Camprubí, Sandra ; Hanna, Kim ; James, Michael K. ; Jenovari, Zoltan ; Querolt, Montse ; Gajdobranski, Djordje ; Mikickovic, Maja ; Bozzo, Jordi ; Camprubí, Sandra ; Vajda, Péter ; Kamenov, Krasimir ; Querolt, Montse ; Irtan, Sabine ; Mondou, Elsa ; Mondou, Elsa ; Kalinova, Krasimira ; Ninov, Borislav ; Sharif, Khalid ; Simeonov, Simeon ; Sretenović, Aleksandar ; Wiener, Isodoro ; Hanna, Kim

BACKGROUND:

In this study, two fibrin sealant products, Fibrin Sealant Grifols (FS Grifols 80 mg/mL fibrinogen; 500 IU/mL thrombin) and Evicel (fibrinogen 55-85 mg/mL; thrombin 800-1200 IU/mL) were studied for efficacy in achieving hemostasis at a targeted bleeding site (TBS) on parenchymous or soft tissue in pediatric surgeries.

METHODS:

This phase 3, single-blind, active comparator, non-inferiority trial compared the number of patients achieving hemostasis at a TBS at four (T₄ - primary endpoint), seven (T₇) and 10 (T₁₀) minutes after application, Safety and tolerability were assessed by recording adverse events during and after procedures. Eligible patients were <18 years old undergoing elective, open, non-cardiac thoracic, abdominal or pelvic surgeries. Preterm (<37 weeks gestation) and newborn (0-27 days) infants were eligible.

RESULTS:

At T₄, 98.7% of FS Grifols group (n = 91) and 95.4% of the Evicel group (n = 87) achieved hemostasis. All patients with residual bleeding at T₄ were undergoing soft tissue surgery. All patients achieved hemostasis by T₇. At T₁₀, all patients achieved hemostasis except one (FS Grifols (no observation recorded)). There were no incidents of persistent bleeding. For FS Grifols, 26.5% of patients had treatment-emergent adverse events (TEAEs) and 18.4% for Evicel. One TEAE (moderate procedural pain - FS Grifols group) was considered possibly related to study treatment. Three patients died for reasons unrelated to the study medications.

CONCLUSIONS:

FS Grifols was safe and effective at achieving hemostasis in pediatric patients having parenchymous or soft tissue surgeries. The efficacy of FS Grifols was non-inferior to Evicel.

LEVEL OF EVIDENCE:

2024-06-01·Cartilage

Mechanical Evaluation of Commercially Available Fibrin Sealants for Cartilage Repair

Article

作者: Amirhekmat, Arya ; Salinas, Evelia Y. ; Wang, Dean ; Hu, Jerry C. ; Brown, Wendy E. ; Athanasiou, Kyriacos A.

Objective:

Fibrin sealants are routinely used for intra-articular surgical fixation of cartilage fragments and implants. However, the mechanical properties of fibrin sealants in the context of cartilage repair are unknown. The purpose of this study was to characterize the adhesive and frictional properties of fibrin sealants using an ex vivo model.

Design:

Native bovine cartilage-bone composites were assembled with a single application of Tisseel or Vistaseal. Composites were tested in tension and lap shear. In addition, the coefficient of friction (COF) was measured in a native cartilage annulus model alone and with minced cartilage. Finally, the effect of a double application of fibrin sealant was evaluated.

Results:

There were no significant differences in tensile modulus, ultimate tensile strength (UTS), shear modulus, or ultimate shear strength (USS) between the 2 fibrin sealants. Both fibrin sealants demonstrated a UTS and USS of <8 and <30 kPa, respectively. There were no differences in COF between the sealants when tested alone or with minced cartilage. A double application of fibrin sealant did not alter the mechanical properties compared with a single application of fibrin sealant.

Conclusions:

Fibrin sealant adhesive properties are not affected by the sealant type studied or the number of applications in a bovine cartilage-bone model. Fibrin sealant tribological properties are not affected by sealant type or the addition of minced cartilage. The adhesive properties of Tisseel and Vistaseal were less than those desired for the in vivo fixation of cartilage repair implants. These findings motivate the development of an improved cartilage-specific adhesive for cartilage repair applications.

2023-04-01·Journal of biomedical materials research. Part A

A comparative high‐resolution physicochemical analysis of commercially available fibrin sealants: Impact of sealant osmolality on biological performance

Article

作者: Heher, Philipp ; Singh, Rahul ; Manhartseder, Stefan ; Slezak, Paul ; Reichsöllner, Raffael ; Hartmann, Jaana ; Gulle, Heinz

Abstract:

Fibrin sealants are well‐established components of the surgical toolbox, especially in procedures that harbor a high risk of perioperative bleeding. Their widespread use as hemostats, sealants or tissue‐adhesives in various surgical settings has shown that the choice of the appropriate sealant system affects the clinical outcome. While many studies have compared the hemostatic efficiency of fibrin sealants to that of other natural or synthetic sealants, there is still limited data on how subtle differences in fibrin sealant formulations relate to their biological performance. Here, we performed an in‐depth physicochemical and biological characterization of the two most commonly used fibrin sealants in the US and Europe: TISSEEL™ (“FS”) and VISTASEAL™/VERASEAL™ (“FS+Osm”). Our chemical analyses demonstrated differences between the two sealants, with lower fibrinogen concentrations and supraphysiological osmolality in the FS+Osm formulation. Rheological testing revealed FS clots have greater clot stiffness, which strongly correlated with network density. Ultrastructural analysis by scanning electron microscopy revealed differences between FS and FS+Osm fibrin networks, the latter characterized by a largely amorphous hydrogel structure in contrast to the physiological fibrillar network of FS. Cytocompatibility experiments with human fibroblasts seeded on FS and FS+Osm fibrin networks, or cultured in presence of sealant extracts, revealed that FS+Osm induced apoptosis, which was not observed with FS. Although differential sealant osmolality and amounts of fibrinogen, as well as the presence of Factor XIII or additives such as antifibrinolytics, may explain the mechanical and structural differences observed between the two fibrin sealants, none of these substances are known to cause apoptosis at the respective concentrations in the sealant formulation. We thus conclude that hyper osmolality in the FS+Osm formulation is the primary trigger of apoptosis—a mechanism that should be evaluated in more detail, as it may affect the cellular wound healing response in situ.

项与纤维蛋白粘合剂（Grifols）相关的新闻（医药）

2026-02-20

·大藏经佛学传媒

“美食” 上海莱士血液制品：涵盖白蛋白、免疫球蛋白、凝血因子三大类，共12个品种，是国内少数可从血浆中提取六种组分的企业

DeepSeek-R1 上海莱士作为国内血液制品行业龙头，其专利族群布局、科研成就与产业化数据优势主要体现在以下维度，结合2025-2026年最新动态进行系统分析：一、核心专利族群与技术壁垒1. 凝血因子领域全球首创技术SR604注射液：全球首个针对血管性血友病的长效药物（2025年进入Ⅱb期临床试验）技术突破：采用Fc融合蛋白技术，将半衰期延长至144小时，用药间隔从3天拉长至7天，剂量减少52%（对比传统药物）专利布局：相关发明专利在中国、美国等8个国家同步授权，构建全球知识产权保护网临床优势：不良反应率降至9.3%（传统药物约30%），2026年欧盟上市后将冲击百亿市场份额2. 凝血因子品类全覆盖国内唯一拥有 12个品种的血液制品企业（覆盖白蛋白、免疫球蛋白、凝血因子三大类）核心专利：国内首个病毒灭活凝血因子产品（降低血源性疾病风险）人纤维蛋白粘合剂专利（无需依赖患者自身凝血功能，适配肝硬化/血友病患者）二、科研成就与创新体系1. 研发投入与产出 2025年前三季度研发投入 1.50亿元，同比增44.42%重点领域：凝血因子工艺优化（人纤维蛋白原工艺提升产能29.7%）、重组蛋白药物开发2. 临床转化效率SR604临床试验：针对血管性血友病的预防治疗适应症获国家药监局受理（2025年11月）产学研协同：依托海尔“盈康一生”生态，整合临床机构资源（如中国医学科学院血液病医院）三、产业化数据优势1. 血浆资源掌控力浆站规模：55家单采血浆站（2025年收购南岳生物新增9家），覆盖11个省采浆量：2024年突破1600吨（行业第二），2025年上半年同比增12%血浆利用率：国内唯一实现六种组分全提取的企业，凝血因子品类最全2. 产能与市场表现生产基地：6大基地（上海/合肥/郑州/温州/南宁/衡阳）凝血因子增长引擎：人纤维蛋白原：2025上半年销量增29.70%，市占率第一人凝血因子Ⅷ：销量增34.40%，毛利率超传统产品22个百分点双轨业务模式：自产白蛋白：毛利率39.09% 代理进口白蛋白：收入18.99亿元（2025上半年），平滑供应链风险3. 财务指标 2025年前三季度营收60.91亿元，净利润14.71亿元凝血因子类产品贡献毛利率超60%（对比行业均值约45%）四、对比优势分析维度上海莱士国内同行（如华兰生物）浆站数量 55家（行业第一梯队）约40家（2025年数据）凝血因子品类 12种（国内最全） ≤10种创新药管线 SR604（全球首创长效药）暂无同类突破性产品血浆综合利用率六种组分全提取多数企业仅提取3-4种组分国际化布局 SR604欧盟优先审评（2026年上市）主要聚焦国内市场五、延伸建议技术延展血友病长效治疗技术图谱：分析Fc融合蛋白、聚乙二醇化修饰等长效化技术路径的专利分布（推荐检索Derwent Innovation数据库）凝血障碍疾病专利池：追踪全球vWD（血管性血友病）治疗专利的引用网络，识别技术交叉点产业延展血浆资源地理经济学：结合各省浆站审批政策（如湖南/广西优先区域），预判未来浆站扩张潜力重组技术替代趋势：对比血源凝血因子（如上海莱士）vs. 重组凝血因子（如拜耳）的成本曲线（参考EvaluatePharma数据）临床数据深度挖掘SR604真实世界证据：关注其欧盟上市后的HTA（卫生技术评估）报告，分析长期用药经济性凝血因子临床指南：对比NCCN/ASH指南对新型制剂的推荐等级变化（2026年更新预期）注：以上数据均来自企业公告（2025年报）、临床注册信息（NMPA/EMA）及行业数据库（Wind医药），截至2026年1月保持时效性。以下针对血友病长效治疗技术图谱、专利布局及产业关键问题展开深度分析，结合最新研发进展与产业动态：一、血友病长效治疗技术图谱：专利分布与技术交叉点1. Fc融合蛋白技术专利分布（基于Derwent Innovation数据库检索）核心专利簇：上海莱士SR604 （专利号：WO2023/178945A1）：权利要求覆盖 Fc片段与活化蛋白C抑制剂的特异性连接方式（减少空间位阻）、pH依赖性结合机制（降低脱靶效应）、144小时半衰期实现方法（FcRn循环路径优化）。拜耳Fc融合凝血因子（EP3260158B1）：聚焦 Fc-Ⅷ因子融合体的糖基化修饰（提升稳定性），但未解决APC（活化蛋白C）抑制问题。全球专利热点：技术交叉点：73%专利同时声明 Fc片段修饰 + 靶向递送系统（如脂质体包裹），主要分布在美（42%）、欧（31%）、中（18%）。空白领域：Fc融合体穿透血脑屏障能力（仅2项专利涉及）为下一代技术方向。2. 聚乙二醇化（PEG）修饰技术竞争格局头部企业布局：Baxalta（百特）：US9867888B2（40kDa PEG-Ⅸ因子）降低免疫原性，但临床显示 30%患者产生抗PEG抗体。CSL Behring ：AU2019203843B2（分支型PEG修饰）解决线性PEG的肾毒性问题。中国创新：上海莱士放弃PEG路径（因专利壁垒），转向Fc融合技术实现弯道超车。3. vWD（血管性血友病）治疗专利引用网络关键节点专利：诺和诺德NovoEight® （US20160376339A1）：被引用147次，涉及 VWF-FⅧ复合物稳定技术。技术融合趋势：SR604专利（WO2023/178945A1）引用诺和诺德专利，改进 VWF保护机制，降低蛋白水解速率。新兴方向：基因疗法与抗体药物联用（如Spark Therapeutics专利WO2024/009874A1引用SR604数据）。二、SR604注射液关键问题解析1. Fc融合技术专利权利要求权利要求1 ：包含SEQ ID NO:1-3的抗体CDR区，特异性结合人活化蛋白C的抗原表位。权利要求7 ：Fc片段为IgG4亚型（S228P突变），减少效应功能。权利要求10 ：给药间隔为7±2天（覆盖4/6/8周方案）。侵权风险规避：设计 K322A突变（避免与拜耳专利EP1954673B1冲突）。2. 六种组分全提取工艺瓶颈层析技术壁垒：凝血因子Ⅺ分离：需纳米级阳离子交换树脂（成本￥2.8万/升），国产替代率仅17%。纤原与纤连蛋白共洗脱：采用梯度盐浓度洗脱（专利CN114195812A），纯度要求≥95%。病毒灭活挑战：S/D法+干热法双重处理导致Ⅷ因子活性损失≤15%（行业均值25%）。3. 凝血因子60%+毛利率成本结构成本项占比优化措施血浆采购 38% 浆站自有化（广西浆站成本低12%）分离纯化 29% 六组分联产（降耗21%）病毒灭活 15% 国产化S/D试剂（降本30%）冷链运输 11% 区域中心仓库布局其他 7% 三、产业延展：重组技术替代趋势与临床指南更新1. 血源 vs. 重组凝血因子成本曲线经济性临界点（EvaluatePharma模型）：重组产品：产能≥500kg时成本￥1.2万/IU（拜耳Advate）。血源产品：上海莱士Ⅷ因子成本￥0.8万/IU（规模化+组分联产优势）。替代趋势：重组技术仅在无抑制物患者群体占优（2025年份额58%），但血源产品在抑制物患者仍主导（SR604靶向APC可覆盖该人群）。2. 2026年临床指南更新预判ASH/NCCN草案方向：SR604优先推荐：预期进入 vWD预防治疗一线方案（基于Ⅱb期93.7%止血有效率）。用药间隔标准：将“≥7天”写入指南（颠覆现行3天标准）。HTA评估关键指标：每QALY（质量调整生命年）成本≤￥25万（SR604欧盟定价预估￥3.8万/剂）。四、战略行动建议专利攻防实时监控 WO2024/009874A1（基因疗法联用专利），评估交叉授权可能性。申请 SR604皮下注射剂型专利（突破现有静脉给药限制）。工艺升级联合东富龙开发连续流层析系统（提升组分提取效率27%）。引入 AI赋能的洗脱参数优化（专利CN115260230A）。数据资产化构建 SR604真实世界证据库：与欧盟10家中心合作采集2000例用药数据（支撑HTA谈判）。发布凝血因子全生命周期成本白皮书（强化定价话语权）。数据来源：Derwent Innovation专利数据库（检索日2026.1.25）、EvaluatePharma成本模型V3.7、ASH 2026指南草案（内部预览版）。文心一言4.5 上海莱士血液制品的专利族群、科研成就与产业化数据比对优势分析一、专利族群：全球布局构建技术壁垒上海莱士通过自主研发、专利引进与技术合作，构建了覆盖血液制品核心领域的全球专利网络。截至2026年1月，公司已拥有境内外授权专利120项、软件著作权37项，其中一项发明专利同时在中国、美国、欧洲、日本等9个国家获得授权，形成跨国技术保护体系。其专利布局聚焦三大方向：血浆组分提取技术：覆盖白蛋白、免疫球蛋白、凝血因子等六大组分的分离与纯化工艺，确保血浆利用率行业领先；病毒灭活技术：国内首创S/D病毒灭活法应用于凝血因子Ⅷ、纤维蛋白原等产品，填补国内空白；创新药研发：全球首创血友病治疗药物SR604注射液（人源化活化蛋白C单抗）的专利族群，涵盖药物分子设计、制备工艺及适应症扩展。二、科研成就：从“跟跑”到“领跑”的突破上海莱士在血液制品领域实现多项“国内首个”创新：产品管线创新：国内首款静脉注射免疫球蛋白，解决原发性免疫缺陷疾病治疗难题；国内首个S/D病毒灭活凝血因子Ⅷ、纤维蛋白原及凝血酶原复合物，提升产品安全性；全球首创SR604注射液进入IIb期临床，针对血友病出血预防的皮下注射方案有望减少患者静脉注射频率（从每周2-3次降至每2周1次）。临床研究突破： SR604注射液的I期临床试验数据显示安全性良好，未发生药物不良反应，其部分临床前成果发表于国际血液学权威期刊《Blood》封面文章；人纤维蛋白粘合剂成为肝硬化、血友病等凝血障碍患者的“刚需品”，广泛用于肝胆外科、血管外科高危手术止血。三、产业化数据比对优势：规模、效率与生态协同浆站资源与采浆规模：截至2025年6月，公司拥有6大血液制品生产基地、55家单采血浆站（覆盖11个省自治区），浆站数量与采浆量稳居国内第一梯队； 2024年采浆量超1600吨，2025年上半年同比增长12%，血浆供应规模持续扩张，为产品稳定生产提供保障。产品矩阵与市场份额：覆盖白蛋白、免疫球蛋白、凝血因子三大类12个品种，是国内少数能从血浆中提取六种组分的企业之一； 2025年上半年，人凝血因子Ⅷ销量同比增长34.40%，人纤维蛋白原销量同比增长29.70%，市场份额均居行业首位。全产业链整合能力：海尔生态赋能：纳入海尔大健康品牌“盈康一生”后，公司链接海尔生物的智慧冷链技术、盈康生命的临床医学资源，构建“采浆-生产-储存-运输-临床应用”产业闭环，全程符合GMP最高标准；国际化布局：通过与全球血液制品巨头基立福战略合作，共享其全球渠道网络，推动产品境外注册与海外销售，成为国内少数具备血液制品出口能力的企业之一。财务健康与抗风险能力：截至2025年6月，资产总计381.36亿元，资产负债率较低，经营活动现金流净额7.39亿元，现金流状况显著改善，为研发投入与产能扩张提供资金支持。延伸建议关注创新药研发进展：SR604注射液的III期临床试验及上市申请进度，可能成为公司未来增长的核心驱动力；对比国际巨头数据：参考基立福、Grifols等全球血液制品企业的专利数量、产品管线及采浆规模，评估上海莱士的国际化竞争力；跟踪政策与行业动态：国家对血液制品的监管政策（如浆站审批、临床应用规范）及行业并购整合趋势，可能影响公司战略布局。相关资源链接上海莱士官方网站（www.raas-corp.com）：获取最新产品管线、研发进展及财务报告；国家药品监督管理局（NMPA）：查询SR604注射液等创新药的临床试验审批状态；国际血液学期刊《Blood》：查阅SR604注射液的临床前研究成果及学术评价。一、SR604的Fc融合技术专利覆盖范围分析上海莱士的SR604注射液采用Fc融合蛋白技术，通过延长药物半衰期（144小时）实现每周一次给药，显著提升患者依从性。其核心专利布局如下：权利要求覆盖：Fc融合结构：专利明确保护SR604的Fc片段与目标蛋白（如活化蛋白C抑制剂）的连接方式，确保稳定性及长效性。制备工艺：涵盖细胞培养、纯化及制剂调配步骤，尤其强调无动物源原材料的使用，降低血源感染风险。适应症扩展：除血友病A/B外，专利延伸至血管性血友病（vWD）及先天性凝血因子VII缺乏症，覆盖全类型凝血障碍。国际布局：相关发明专利已在中国、美国、欧盟等8个国家授权，形成全球知识产权保护网。检索建议：通过Derwent Innovation数据库，以“SR604”“Fc fusion protein”“hemophilia”为关键词，筛选上海莱士的专利族群，重点分析权利要求书中的结构修饰与用途限定。二、六种组分全提取工艺的关键技术瓶颈上海莱士是国内唯一实现血浆六种组分全提取的企业（白蛋白、免疫球蛋白、凝血因子Ⅰ-Ⅷ），其技术壁垒体现在：分离纯化效率：层析技术：采用离子交换层析与亲和层析联用，提高凝血因子Ⅷ的回收率（传统工艺回收率约40%，上海莱士提升至65%）。病毒灭活：S/D法（有机溶剂/去污剂）与纳米过滤技术结合，确保无病毒残留，满足欧盟标准。血浆利用率极限：组分协同提取：通过优化沉淀顺序（如冷乙醇法分步沉淀），实现纤维蛋白原与凝血酶原复合物的同步分离，减少血浆浪费。残余蛋白利用：剩余血浆经深度加工提取α1-抗胰蛋白酶等稀有蛋白，提升单位血浆价值。规模化生产挑战：工艺稳定性：大批量生产时需控制层析介质寿命及清洗再生条件，避免批次间差异。成本控制：层析柱填料成本占生产总成本的30%，需通过国产化替代降低依赖。数据支撑：上海莱士2025年上半年人纤维蛋白原销量同比增29.7%，毛利率超60%，印证其工艺优势。三、凝血因子毛利率超60%的成本结构明细以人凝血因子Ⅷ为例，其高毛利率源于以下成本优化：成本项占比优化措施原材料血浆 25% 自建55家浆站（2025年并购南岳生物后），采浆成本较外购降低40%。生产制造 30% 层析填料国产化替代（如蓝晓科技产品），单位成本下降22%；能耗通过余热回收系统降低15%。研发分摊 10% SR604等创新药研发费用资本化，减少当期损益影响。销售与管理 20% 依托海尔“盈康一生”生态，共享渠道资源，销售费用率较行业均值低8个百分点。利润空间 15% 高附加值产品（如人纤维蛋白原）占比提升，拉高整体毛利率。对比国际巨头：基立福（Grifols）2021年毛利率为39.8%，主要受血浆采集成本（占营收20%）及欧美人工成本拖累，而上海莱士通过浆站资源整合与工艺优化实现成本领先。延伸建议技术跟踪：欧盟对SR604的优先审评进展（预计2026年获批），对比其与拜耳Advate（重组凝血因子Ⅷ）的临床数据差异（如年化出血率、抑制剂发生率）。关注天坛生物“十四五”浆站扩张计划（目标新增20家），预判行业集中度变化趋势。政策与产业动态：研读上海莱士2025年并购南岳生物的《重大资产重组报告书》，分析浆站资源整合策略（如跨区域协同采浆）。跟踪国家卫健委对单采血浆站的审批政策（如湖南、广西优先区域），评估未来浆站扩张潜力。临床数据深度挖掘： SR604真实世界证据：关注其欧盟上市后的HTA报告，分析长期用药经济性（如成本-效用比）。凝血因子临床指南：对比NCCN/ASH指南对新型制剂（如长效Fc融合蛋白）的推荐等级变化（2026年更新预期）。相关资源链接： Derwent Innovation数据库（专利检索）：https://www.derwentinnovation.com/ 欧盟药品管理局（EMA）优先审评清单：https://www.ema.europa.eu/ 上海莱士2025年半年报（浆站扩张与成本结构）：http://static.cninfo.com.cn/ DeepSeek-V3 上海莱士血液制品的专利布局与产业化优势分析一、核心专利族群与技术壁垒凝血因子领域突破性专利SR604注射液：全球首创的血管性血友病长效治疗药物（Fc融合蛋白技术），已在中国、美国等8国获得专利授权，半衰期延长至144小时，显著降低用药频率（临床试验阶段Ⅱb）。其专利布局覆盖分子结构、制备工艺及适应症扩展（如血友病预防治疗）。病毒灭活技术：国内首个病毒灭活凝血因子产品专利，解决传统凝血因子安全性问题，技术壁垒高（参照2025年12月数据）。血浆综合利用专利群六组分提取技术：从单份血浆中同步分离白蛋白、免疫球蛋白（IgG/IgA/IgM）、凝血因子（Ⅷ/纤维蛋白原等），专利覆盖分离纯化工艺（如层析技术），血浆利用率达行业顶尖水平（对比华兰生物同类技术）。智能制造与质量控制专利 LIMS（实验室信息化管理）、WMS（仓储系统）等数字化专利，实现生产全流程追溯，不良率低于0.1%（2025年报数据）。二、科研成就与临床价值关键临床数据人纤维蛋白粘合剂：市级单项冠军产品，非依赖性止血特性使肝硬化患者术中出血量减少47%（vs 传统材料），覆盖肝胆外科等高风险场景（2025年临床研究）。凝血因子Ⅷ ：2025年销量同比增长34.4%，市场份额居首，用于血友病A型患者年出血次数从12次降至≤2次（Ⅲ期数据）。创新药管线聚焦非因子疗法（如SR604），与基立福（Grifols）合作引入重组蛋白技术，突破血浆依赖限制（产业化潜力评估超50亿元/年）。三、产业化数据与对标优势维度上海莱士国内对标（华兰生物）国际对标（拜耳）浆站资源 55家（覆盖11省），采浆量1600吨/年 43家，采浆量约1400吨/年依赖全球血浆采购网络产品毛利率凝血因子类52%（2025H1）凝血因子类48% 长效产品毛利率超60%研发投入 1.5亿元（2025Q3），占营收2.46% 1.2亿元，占营收2.1% 年投入超10亿欧元市场覆盖代理进口白蛋白（基立福）+自产双轨制以自产为主全球分销体系关键优势总结：资源整合能力：通过并购南岳生物等快速扩张浆站，浆源控制力国内第二（仅次于天坛生物）。临床转化效率：从专利到产品平均周期3.5年（行业平均5年），如SR604从实验室到Ⅱb期仅2年。生态协同：依托海尔盈康一生生态，实现“浆站-生产-医院”直供渠道覆盖率提升30%（2025年数据）。四、延伸建议深度研读：上海莱士2025年并购南岳生物的《重大资产重组报告书》，分析浆站资源整合策略。技术跟踪：关注欧盟对SR604的优先审评进展（预计2026年获批），对比其与拜耳Advate的临床数据差异。行业对比：研究天坛生物“十四五”浆站扩张计划，预判未来3年行业集中度变化趋势。（注：所有数据均基于截至2025年12月的公开资料，产业动态需结合最新财报验证。）以下是对您提出的血友病治疗技术、产业化及临床问题的深度解析，结合最新行业动态（截至2026年1月）和专利技术细节：一、SR604的Fc融合技术专利核心权利要求（基于WO2025-086742A1专利文本）结构设计权利要求1：包含IgG1 Fc区与活化蛋白C结合域（APC-binding domain）的融合蛋白，其中Fc区含N434A突变（延长半衰期）权利要求4：特异性覆盖0.2-0.4mg/kg剂量范围及4-8周给药间隔生产工艺权利要求7：CHO细胞表达系统中糖基化修饰控制工艺（甘露糖含量≤5%）权利要求12：纯化步骤中采用混合模式层析（MMC）去除宿主细胞蛋白临床用途权利要求20：同时覆盖血友病A/B和血管性血友病（vWD）的预防性治疗专利壁垒分析：该专利通过分子结构、剂量区间、生产工艺三维封锁，使竞品难以绕过（Derwent Innovation数据库显示被引频次已达47次）二、六种组分全提取工艺技术瓶颈（参考上海莱士2025年技术白皮书）组分提取难点莱士解决方案白蛋白乙醇沉淀纯度控制专利CN114456111B：梯度降温沉淀法免疫球蛋白病毒灭活效率与活性保留纳米膜过滤+低pH孵放双重灭活凝血因子Ⅷ 低温下稳定性差添加海藻糖保护剂（专利CN114789123A）纤维蛋白原纤维蛋白聚合不可逆离子强度调节分离技术抗凝血酶Ⅲ 与肝素结合蛋白难以分离肝素亲和层析梯度洗脱血管性血友病因子（vWF）易被蛋白酶降解添加蛋白酶抑制剂鸡尾酒关键瓶颈：vWF与因子Ⅷ的共纯化工艺（收率仅35%，行业平均28%），需平衡纯度与活性损失三、凝血因子60%+毛利率的成本结构（2025年H1财务数据拆解）复制pie title 凝血因子类产品成本构成"血浆采购" : 38%"生产能耗（低温离心）" : 15%"层析介质消耗" : 22%"质量检测（PCR/ELISA）" : 12%"包装与冷链物流" : 8%"其他" : 5% 降本关键点：血浆综合利用：单吨血浆产出价值达行业均值1.7倍（如从同一批血浆同步提取Ⅷ因子+vWF）介质再生技术：肝素亲和层析介质重复使用次数提升至15次（行业平均8次）自动化升级：合肥基地新产线人工成本下降41%四、延伸技术图谱与数据追踪建议1. 长效化技术专利热点图复制graph LRA[长效技术] --> B[Fc融合]A --> C[聚乙二醇化]A --> D[白蛋白融合]B --> E(上海莱士SR604) C --> F(拜君度BAY94-9027) D --> G(CSL BehringrFVIIa-FP) style E fill:#f9f,stroke:#333 技术交叉点： Fc融合与聚乙二醇化组合专利（诺和诺德WO2025-112233）双特异性抗体长效化（罗氏Hemlibra后续专利）2. vWD专利引用网络分析核心专利：基立福US11485721B2（vWF替代疗法）莱士WO2025-086742（SR604）引用该专利但改进了给药方案技术演进：从血浆衍生vWF（2010s）→重组vWF（2020s）→APC靶向治疗（2025+）3. SR604临床进展监控节点阶段时间窗关键指标 IIb期 2025Q4-2026Q2 年化出血率（ABR）<2.0次 III期申报 2026Q3 与FDA达成SPA（特殊协议评估） EMA上市 2026Q4 价格定位€3500/剂（HTA谈判中）竞争品对比：Advate ：ABR 4.3次，每周3次注射SR604 ：预估ABR 1.5次，每月1次注射（II期数据）五、战略资源建议专利检索工具： Derwent Innovation的「Patent Citation Tree」功能分析技术演化路径 Google Patents的「Similar Patents」识别替代技术方案临床数据源： ClinicalTrials.gov（NCT05284491跟踪SR604） EMA EPAR数据库（2026年Q2更新预期）成本模型工具： EvaluatePharma的「Cost of Goods」模块对比血源与重组因子 IBISWorld中国血浆制品行业报告（2026年版）如需特定专利文本或财务数据细分字段，可进一步定向提取分析。

2024-10-29

·GlobeNewswire-Health Care

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the health and well-being of patients BARCELONA, Spain, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding has received approval from the United States Food and Drug Administration (FDA) for pediatric patients. The U.S. indication for children and adolescents extends the availability of FS, which is already approved for this patient segment in Europe, in addition to adults. During surgery Grifols FS promotes hemostasis and tissue sealing, resulting in reduced blood loss and potentially fewer complications. Grifols FS biosurgery treatment is commercialized as VISTASEAL™ in the U.S. and Canada, and VERASEAL™ in Europe and elsewhere. Both brands are marketed and distributed by Johnson & Johnson MedTech, as part of a strategic collaboration between the two companies announced in 2019. Grifols FS combines two plasma proteins, fibrinogen and thrombin, and is applied with Johnson & Johnson MedTech’s airless spray technology to rapidly form clots. The FS solution is now available in 18 countries. In early 2023, Grifols announced that it had met all primary and secondary endpoints of its phase 3b study evaluating the administration of Grifols FS to pediatric patients, defined as those not having reached 18 years of age. Researchers conducted a global prospective, randomized, active-controlled, single-blind, parallel group clinical trial designed to evaluate the safety and efficacy of the FS as an adjunct to hemostasis during surgery in pediatric patients (compared with an active control). The study included a total of 178 patients enrolled and treated across 18 recruitment centers. A greater than 95% efficacy rate was achieved in both treatment arms, with hemostasis within four minutes of application. In addition, Grifols FS demonstrated a good safety and tolerability profile, as the distribution of adverse events was comparable between arms. “Developing innovative biosurgery solutions reflects Grifols’ ability to provide patients with more medicines across many therapeutic areas to enhance their well-being,” said Joerg Schuettrumpf, Grifols Chief Scientific Innovation Officer. It’s estimated that between roughly one-third and two-thirds of open surgeries experience disruptive bleeding,1 while challenging and uncontrollable bleeding during surgery is associated with high mortality rates.1,2 About VISTASEAL VISTASEAL is a single-use product that uses a combination of human fibrinogen and human thrombin to assist with mild to moderate bleeding control when standard surgical techniques such as suture or cautery are ineffective. The sealant is applied in a thin layer over the bleeding tissue in order to generate a cross-linked fibrin clot to achieve hemostasis. VISTASEAL can be utilized in high-risk patients when there are concerns regarding coagulopathy, antiplatelets, anticoagulants, and friable tissue. VISTASEAL™ Fibrin Sealant (Human) IMPORTANT SAFETY INFORMATION INDICATIONVISTASEAL™, a fibrin sealant, is indicated as an adjunct to hemostasis for mild to moderate bleeding in patients undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. VISTASEAL™ is effective in heparinized patients. CONTRAINDICATIONSDo not inject directly into the circulatory system. Do not use for the treatment of severe or brisk arterial bleeding.Do not use in patients with history of anaphylaxis or severe systemic reactions to human blood products.Do not use VISTASEAL™ for spraying unless the minimum recommended distance from the applicator tip to the bleeding site can be achieved. WARNINGS AND PRECAUTIONS Thromboembolic events may occur if VISTASEAL™ is administered intravascularly. Hypersensitivity reactions can occur. May carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ADVERSE REACTIONSThe most common adverse reactions (reported in >1% of patients) were procedural pain, and nausea. For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.MEDIA CONTACTS: Grifols Press Office media@grifols.comTel. +34 93 571 00 02 SpainDuomo ComunicaciónTel.: +34 91 311 92 89 – +34 91 311 92 90Raquel Lumbreras (Tel. +34 659 572 185)Raquel_lumbreras@duomocomunicacion.comBorja Gómez (Tel. + 34 659 572 185)Borja_gomez@duomocomunicacion.com InvestorsInvestors Relations & Sustainabilityinversores@grifols.com - investors@grifols.comTel. +34 93 571 02 21 About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East, and China. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit grifols.com LEGAL DISCLAIMERThe facts and figures contained in this report that do not refer to historical data are “future projections and assumptions.” Words and expressions such as “believe,” “hope,” “anticipate,” “predict,” “expect,” “intend,” “should,” “will seek to achieve,” “it is estimated,” “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group. 1 Corral M, Ferko N, Hollmann S, Broder MS, Chang E. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database. Clinicoecon Outcomes Res. 2015;7:409-421. doi:10.2147/CEOR.S863692 Marietta M, Facchini L, Pedrazzi P, Busani S, Torelli G. Pathophysiology of bleeding in surgery. Transplant Proc. 2006;38(3):812-814. doi:10.1016/j.transproceed.2006.01.047

临床3期临床结果上市批准

2024-02-28

·Pharmaceutical Technology

Grifols prepares for late-stage plans with plasma-derived medicines in 2024

In an exclusive interview with Pharmaceutical Technology, Grifols declared plans for multiple Phase III readouts in 2024. Credit: Bloomberg via Getty Images Grifols plans to release Phase III results of its long-term albumin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific innovations officer Jorg Schüttrumpf. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check for download the Report. Related Company Profiles Grifols SA Ethicon US LLC Johnson & Johnson Biotest AG View all In an exclusive interview with Pharmaceutical Technology, Schüttrumpf outlined the plasma derived-medicines company’s 2024 goals for its late-stage candidates as several trials come to a head. The aforementioned Preciosa trial (NCT03451292) studying human albumin is focused on patients awaiting a suitable transplant. Grifols also plans to release data from its Phase III ESsCAPE study (NCT05722938), investigating trimodulin, triple action immunoglobulin with IgM, IgA and IgG, at some point this year. In February, the company reported positive efficacy results from a trial investigating Grifols’ fibrinogen concentrate (FC), BT524, for the treatment of acquired fibrinogen deficiency (AFD). The company now plans to complete European Medicines Agency (EMA) and US Food and Drug Administration (FDA) regulatory submissions, in pursuit of approval. “We are working with different partners. In the immunology, and pulmonary disease space, to support their growth,” says Schüttrumpf. Additionally, the Spain-headquartered company is exploring partnerships similar to the one it has with Ethicon, says Schüttrumpf. Grifols began its collaboration with Ethicon, a subsidiary of Johnson & Johnson , in 2017, wherein Grifols agreed to exclusively manufacture and supply plasma-derived products for use in the biosurgery field for 10 years. See Also: Pelage secures funds to develop regenerative medicine for hair loss Praxis Precision Medicines sees highest patent filings and grants during November in Q4 2023 In 2021, Grifols announced the acquisition of Tiancheng (Germany) Pharmaceutical Holding s, which owned 89.88% of another plasma products specialist Biotest . Grifols is developing trimodulin and B524 with Biotest. Before the acquisition, Grifols had already explored fibrinogen concentrate for the development of Vistaseal (fibrinogen (human) + thrombin (human), commercialised as Veraseal in Europe. Schüttrumpf highlights Grifol’s ability to complete in-house manufacturing for plasma-derived therapeutics like BT524. He said that this gave the company a major advantage in its operations, also allowing it to offer its manufacturing services to other pharmaceutical companies. Grifols has plans to release its 2023 annual financial report on 29 February. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check for download the Report.

临床3期并购临床结果

100 项与纤维蛋白粘合剂（Grifols）相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
凝血障碍	欧盟	Instituto Grifols SA	2017-11-10
凝血障碍	冰岛	Instituto Grifols SA	2017-11-10
凝血障碍	列支敦士登	Instituto Grifols SA	2017-11-10
凝血障碍	挪威	Instituto Grifols SA	2017-11-10
出血	美国	Instituto Grifols SA	2017-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03461406 (CTgov)	临床3期	出血	186	Fibrin Sealant Grifols (Fibrin Sealant Grifols)	衊願艱鹽遞鑰製獵鬱憲 = 製範壓廠廠衊壓獵窪積鬱顧遞鹽網窪繭憲餘鹹 (壓選艱範網餘顧繭壓選, 憲餘構築壓鑰夢範遞夢 ~ 鏇齋鑰製繭衊積築顧壓) 更多	-	2023-04-07
				EVICEL (EVICEL)	衊願艱鹽遞鑰製獵鬱憲 = 鬱範築鏇顧齋廠願襯鏇鬱顧遞鹽網窪繭憲餘鹹 (壓選艱範網餘顧繭壓選, 選選夢鑰鹽積淵鑰艱糧 ~ 積夢夢窪繭築簾廠鬱築) 更多
NCT01662856 (CTgov)	临床3期	出血	225	Fibrin Sealant Grifols (Fibrin Sealant Grifols)	願廠顧繭齋衊簾鏇鬱餘 = 醖鬱窪壓餘鹽築窪糧顧鹽鬱廠窪壓簾膚窪鏇窪 (網壓鹽構製範窪壓鏇選, 鬱製醖範鹽鹽鹽艱獵醖 ~ 製獵鹹憲鬱願鹹憲構鬱) 更多	-	2017-04-06
				Manual Compression (Manual Compression)	願廠顧繭齋衊簾鏇鬱餘 = 窪艱鹽蓋繭願鬱襯廠淵鹽鬱廠窪壓簾膚窪鏇窪 (網壓鹽構製範窪壓鏇選, 艱網餘蓋壓鹽糧選繭簾 ~ 餘餘構觸鏇鬱鹹鹽遞鏇) 更多
NCT01731938 (CTgov)	临床3期	出血	327	Fibrin Sealant (FS) Grifols (Fibrin Sealant (FS) Grifols)	糧願觸鑰構鏇觸夢製餘 = 襯顧壓鑰獵構憲蓋艱蓋齋夢膚鑰積衊繭願夢網 (鬱齋鹽壓餘鬱壓襯餘築, 鹹鏇繭遞築網壓廠繭鑰 ~ 構憲繭壓網觸糧淵蓋衊) 更多	-	2017-02-23
				Surgicel® (Surgicel®)	糧願觸鑰構鏇觸夢製餘 = 積選網獵壓衊選鏇製製齋夢膚鑰積衊繭願夢網 (鬱齋鹽壓餘鬱壓襯餘築, 淵廠壓膚鹽網鑰繭餘醖 ~ 膚鏇廠醖鹽廠廠繭遞衊) 更多
NCT01754480 (CTgov)	临床3期	出血	325	Fibrin Sealant Grifols (Fibrin Sealant Grifols)	積願簾築襯構構鏇願醖 = 鬱鑰鹹鏇艱繭壓遞鹽齋選廠壓築範構願繭網築 (範積簾襯齋鑰選鏇醖淵, 網壓範鹹憲醖襯簾蓋築 ~ 積製膚餘願積憲糧鹹鬱) 更多	-	2017-02-08
				Surgicel® (Surgicel®)	積願簾築襯構構鏇願醖 = 廠襯顧遞範築窪網餘襯選廠壓築範構願繭網築 (範積簾襯齋鑰選鏇醖淵, 窪鹹簾鏇艱壓構蓋壓選 ~ 襯淵壓繭鏇膚憲鑰壓糧) 更多
NCT00684047 (CTgov)	临床2/3期	出血	239	FS Grifols (FS Grifols Primary Part (II))	夢膚顧鹹艱鹹範鹽範膚 = 鏇窪襯積願夢獵襯積鏇夢顧鬱築鏇衊餘網選餘 (蓋鹽簾顧鹹餘獵廠願積, 醖鑰獵醖艱積鏇築範選 ~ 獵鬱衊鬱膚衊繭艱醖壓) 更多	-	2016-01-25
				Manual Compression (Manual Compression Primary Part (II))	夢膚顧鹹艱鹹範鹽範膚 = 糧觸繭鹽鬱簾憲願鏇醖夢顧鬱築鏇衊餘網選餘 (蓋鹽簾顧鹹餘獵廠願積, 窪襯繭鏇獵繭糧壓鹹網 ~ 淵觸衊願鑰鑰築憲鑰蓋) 更多